FACTOR XA
FACTOR XA structure
|
Common Name | FACTOR XA | ||
|---|---|---|---|---|
| CAS Number | 9002-05-5 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | USA | Flash Point | N/A | |
|
Dabigatran, ROCKET atrial fibrillation, and beyond: basic science, mechanisms of agents, monitoring, and reversal.
Stroke 44(6 Suppl 1) , S38-40, (2013)
|
|
|
Safety of Short-Term Use ofDabigatranorRivaroxabanfor Direct-Current Cardioversion in Patients With Atrial Fibrillation and Atrial Flutter
Am. J. Cardiol. 113(8) , 1362-3, (2014) Direct-current cardioversion (DCCV) for persistent atrial fibrillation or atrial flutter (AF) carries a risk of thromboembolic events (TEs). Therapeutic anticoagulation with warfarin is recommended for 3 to 4 weeks before and 4 weeks after DCCV to reduce TE; ... |
|
|
[From apixaban to aspirin in the prevention of recurrent venous thromboembolism].
Invest. Clin. 54(3) , 231-3, (2013) For more than a decade, the only treatments available for the prevention of recurrent venous thromboembolism, were vitamin K inhibitors, or low molecular weight heparins (LMWH). Both have been very useful for this purpose; however, with the inconvenience of r... |
|
|
Thrombin induces epithelial-mesenchymal transition and collagen production by retinal pigment epithelial cells via autocrine PDGF-receptor signaling.
Invest. Ophthalmol. Vis. Sci. 54(13) , 8306-14, (2013) De-differentiation of RPE cells into mesenchymal cells (epithelial-mesenchymal transition; EMT) and associated collagen production contributes to development of proliferative vitreoretinopathy (PVR). In patients with PVR, intraocular coagulation cascade activ... |
|
|
Phosphatidylserine and FVa regulate FXa structure.
Biochem. J. 459(1) , 229-39, (2014) Human coagulation FXa (Factor Xa) plays a key role in blood coagulation by activating prothrombin to thrombin on 'stimulated' platelet membranes in the presence of its cofactor FVa (Factor Va). PS (phosphatidylserine) exposure on activated platelet membranes ... |
|
|
Active-site mapping of bovine and human blood coagulation serine proteases using synthetic peptide 4-nitroanilide and thio ester substrates.
Biochemistry 23(4) , 644-50, (1984) A series of 14 tripeptide 4-nitroanilide substrates of the type Z-AA-Gly-Arg-NA and Z-AA-Phe-Arg-NA where AA = Ala, Asn, Glu, Lys, Phe, Pro, or Ser were used to map the S3 subsite of several serine proteases involved in blood coagulation. The enzymes studied ... |
|
|
Moving toward a more ideal anticoagulant: the oral direct thrombin and factor Xa inhibitors.
Chest 143(4) , 1106-16, (2013) Thromboembolic diseases are common. Heparins and the vitamin K antagonists have been the mainstay of therapy for > 60 years, but both classes of agents have limitations. The "ideal" anticoagulant should be as effective and safe as heparin and vitamin K antago... |
|
|
The role of serine proteases in the blood coagulation cascade.
Adv. Enzymol. Relat. Areas Mol. Biol. 48 , 277-318, (1979)
|
|
|
Rivaroxaban, a direct inhibitor of the coagulation factor Xa interferes with hormonal-induced physiological modulations in human female osteoblastic cell line SaSO2.
J. Steroid Biochem. Mol. Biol. 135 , 67-70, (2013) The use of anticoagulants has been associated with systemic osteoporosis and increased risk for poor fracture healing but is inevitable following major orthopedic surgery of lower limbs. Rivaroxaban A (R) is an anticoagulant recently introduced in the clinica... |
|
|
14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends.
Autoimmun. Rev. 13(6) , 685-96, (2014) Antiphospholipid Syndrome (APS) is characterized by vascular thrombosis and/or pregnancy morbidity occurring in patients with persistent antiphospholipid antibodies (aPL). The primary objective of the APS Treatment Trends Task Force, created as part of the 14... |